1. Home
  2. ORKT vs IGC Comparison

ORKT vs IGC Comparison

Compare ORKT & IGC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ORKT
  • IGC
  • Stock Information
  • Founded
  • ORKT 2003
  • IGC 2005
  • Country
  • ORKT Singapore
  • IGC United States
  • Employees
  • ORKT N/A
  • IGC N/A
  • Industry
  • ORKT
  • IGC Biotechnology: Pharmaceutical Preparations
  • Sector
  • ORKT
  • IGC Health Care
  • Exchange
  • ORKT NYSE
  • IGC Nasdaq
  • Market Cap
  • ORKT 34.7M
  • IGC 29.4M
  • IPO Year
  • ORKT 2024
  • IGC N/A
  • Fundamental
  • Price
  • ORKT $1.23
  • IGC $0.31
  • Analyst Decision
  • ORKT Strong Buy
  • IGC Strong Buy
  • Analyst Count
  • ORKT 1
  • IGC 2
  • Target Price
  • ORKT $5.00
  • IGC $3.75
  • AVG Volume (30 Days)
  • ORKT 6.9M
  • IGC 390.0K
  • Earning Date
  • ORKT 10-16-2024
  • IGC 02-25-2025
  • Dividend Yield
  • ORKT N/A
  • IGC N/A
  • EPS Growth
  • ORKT N/A
  • IGC N/A
  • EPS
  • ORKT N/A
  • IGC N/A
  • Revenue
  • ORKT $3,904,592.00
  • IGC $1,236,000.00
  • Revenue This Year
  • ORKT N/A
  • IGC N/A
  • Revenue Next Year
  • ORKT N/A
  • IGC $13.38
  • P/E Ratio
  • ORKT N/A
  • IGC N/A
  • Revenue Growth
  • ORKT N/A
  • IGC N/A
  • 52 Week Low
  • ORKT $0.62
  • IGC $0.27
  • 52 Week High
  • ORKT $8.00
  • IGC $0.91
  • Technical
  • Relative Strength Index (RSI)
  • ORKT N/A
  • IGC 42.69
  • Support Level
  • ORKT N/A
  • IGC $0.29
  • Resistance Level
  • ORKT N/A
  • IGC $0.33
  • Average True Range (ATR)
  • ORKT 0.00
  • IGC 0.01
  • MACD
  • ORKT 0.00
  • IGC 0.00
  • Stochastic Oscillator
  • ORKT 0.00
  • IGC 43.20

About ORKT ORANGEKLOUD TECHNOLOGY INC

Orangekloud Technology Inc is a company that operates through its subsidiaries provide IT consultancy services and distribution of related products and services. The Company also offers ERPs predominately in Singapore. It derives revenue from platform subscriptions, license and products and professional services.

About IGC IGC Pharma Inc.

IGC Pharma Inc develops advanced cannabinoid-based formulations for treating diseases and conditions, including, but not limited to, Alzheimer's disease, period cramps, premenstrual syndrome and chronic pain. The company has two investigational drug assets targeting Alzheimer's disease, IGC-AD1 and TGR-63, which have demonstrated in Alzheimer's cell lines the potential to be effective in suppressing or ameliorating key hallmarks of Alzheimer's disease, such as plaques or tangles. IGC-AD1 is a low-dose tetrahydrocannabinol-based formulation that is in a 146-person Phase 2 clinical trial for agitation in dementia due to Alzheimer's. IGC also markets a wellness brand, Holief, that targets women experiencing premenstrual syndrome and menstrual cramps.

Share on Social Networks: